PD-1/PD-L1 Inhibitors Market
Description
PD-1/PD-L1 Inhibitors Market
A recent market study published by Future Market Insights (FMI) on the PD-1/PD-L1 inhibitors market offers global industry analysis for 2015-2021 & opportunity assessment for 2022-2030. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the PD-1/PD-L1 inhibitors market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may make a huge impact on the development of the PD-1/PD-L1 inhibitors market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the PD-1/PD-L1 inhibitors market in the coming years. The report provides detailed information about the current and future growth prospects of the PD-1/PD-L1 inhibitors market in the most comprehensive way for better understanding of readers.
Key Segments of PD-1/PD-L1 inhibitors Market
FMI’s study on the PD-1/PD-L1 inhibitors market offers information divided into four important segments— product, indication, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Product
Nivolumab
Pembrolizumab
Atezolizumab
Avelumab
Durvalumab
Indication
Melanoma
Non-Small Cell Lung Cancer (NSCLC)
Renal Cell Carcinoma (RCC)
Head and Neck Squamous Cell Cancer (HNSCC)
Bladder Cancer
Merkel Cell Carcinoma (MCC)
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Chapter 1 – Executive Summary
The report commences with the executive summary of the PD-1/PD-L1 inhibitors market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the PD-1/PD-L1 inhibitors market as well as the key trends impacting the market.
Chapter 2 – Market Overview
Readers can find detailed taxonomy and product definition of the PD-1/PD-L1 inhibitors market, in this chapter, which help readers understand basic information about PD-1/PD-L1 inhibitors.
Chapter 3 – Key Market Trends
This section highlights the key trends impacting the PD-1/PD-L1 inhibitors market, which will help readers understand the current trends and their impact on market growth.
Chapter 4 – Market Background
This chapter explains the key macroeconomic factors that are expected to influence the growth of the PD-1/PD-L1 inhibitors market during the forecast period. The chapter also highlights the major forecast factors that will shape market growth. Besides, it provides key dynamics of the PD-1/PD-L1 inhibitors market, which include the drivers, restraints, and opportunity analysis. This chapter is expected to enable readers to understand the factors that are propelling the growth of the PD-1/PD-L1 inhibitors market, as well as those that are likely to hamper the growth of the PD-1/PD-L1 inhibitors market. The opportunity analysis for the PD-1/PD-L1 inhibitors will help readers understand the market opportunities, based on which they can plan their strategies.
Chapter 5 – Market Context
This chapter explains the pipeline assessment, key regulations for product launch in various countries along with disease epidemiology that are expected to influence the growth of the PD-1/PD-L1 inhibitors market during the forecast period.
Chapter 6 – COVID19 Crisis Analysis
In addition this section also provides the current and expected impact of COVID19 on the PD-1/PD-L1 inhibitors market.
Chapter 7 – Global PD-1/PD-L1 Inhibitors Market - Pricing Analysis
This section provides information on the pricing analysis from the regional and global prospects, also including pricing break up at distributor and manufacturer level.
Chapter 8 – Global PD-1/PD-L1 inhibitors Market Value (US$) Analysis 2015-2021 and Forecast 2022-2030
This section explains the global market value analysis and forecast for the PD-1/PD-L1 inhibitors market during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2022), and an incremental $ opportunity for the forecast period (2022-2030).
Chapter 9 – Global PD-1/PD-L1 inhibitors Market Analysis (2015-2021) and Forecast (2022-2030), By Product
Based on product, the PD-1/PD-L1 inhibitors market is segmented into nivolumab, pembrolizumab, atezolizumab, avelumab and durvalumab. In this chapter, readers can find information about a detailed analysis of the market by different product of PD-1/PD-L1 inhibitors and their growth over the forecast period.
Chapter 10 – Global PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast, 2022-2030, By Indication
Based on indication, the PD-1/PD-L1 inhibitors market is segmented into Melanoma, Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Head and Neck Squamous Cell Cancer (HNSCC), Bladder Cancer, Merkel Cell Carcinoma (MCC) and others. In this chapter, readers can find information on market attractive analysis based on indication.
Chapter 11 – Global PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast, 2022-2030, By Distribution Channel
Based on distribution channel, the PD-1/PD-L1 inhibitors market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. In this chapter, readers can find information on market attractive analysis based on distribution channel.
Chapter 12 – Global PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, By Region
This chapter explains how the PD-1/PD-L1 inhibitors market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).
Chapter 13 – North America PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
This chapter includes a detailed analysis of the growth of the North America PD-1/PD-L1 inhibitors market along with the country-wise assessment including the U.S. and Canada. Readers can also find key takeaways of this region, and market growth based on product, indication, distribution channel and country of PD-1/PD-L1 inhibitors in the North American region.
Chapter 14 – Latin America PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
This chapter includes the growth prospects of the PD-1/PD-L1 inhibitors market in leading countries such as Brazil, Mexico, and the rest of Latin America. Readers can find thorough information about the growth parameters of the Latin America PD-1/PD-L1 inhibitors market during 2022-2030.
Chapter 15 –Europe PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
Important growth prospects of the PD-1/PD-L1 inhibitors market based on product, indication, distribution channel, and country in several European countries such as the U.K., Germany, France, Italy, Spain, Russia, BENELUX, and Rest of Europe are included in this chapter.
Chapter 16 – South Asia PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
India, Indonesia, Malaysia, Thailand, and the rest of South Asia are the leading countries/regions in South Asia that are the prime subjects of assessment to obtain the growth prospects of the South Asia PD-1/PD-L1 inhibitors market, in this chapter, readers can find thorough information about the growth parameters of the South Asia PD-1/PD-L1 inhibitors market during 2030.
Chapter 17 – East Asia PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
Detailed information about factors such as incremental opportunity, Y-O-Y growth, and regional trends that are impacting the growth of the East Asia PD-1/PD-L1 inhibitors market are included in this chapter. It also includes the growth prospects of the PD-1/PD-L1 inhibitors market in leading East Asian countries such as China, Japan, and South Korea.
Chapter 18 – Oceania PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
This chapter consists of important parameters that have a huge impact on the growth of the PD-1/PD-L1 inhibitors market in Oceania, based on market segmentation, during the forecast period. The chapter also provides an overview of the drivers, restraints, and trends in the Oceania PD-1/PD-L1 inhibitors market.
Chapter 19 – Middle East & Africa PD-1/PD-L1 inhibitors Market Analysis 2015-2021 & Opportunity Assessment 2022-2030
This chapter provides information on how the PD-1/PD-L1 inhibitors market will grow in the major countries in MEA region, such as GCC Countries, South Africa, Northern Africa, Turkey and Rest of MEA during 2022-2030.
Chapter 20 – Key and Emerging Countries PD-1/PD-L1 inhibitors Market Analysis 2022 & 2030
This chapter provides information on how the PD-1/PD-L1 inhibitors market will grow in the major countries across the world during 2022 & 2030.
Chapter 21 – Market Structure Analysis
This chapter covers the market analysis of competitors based on revenue tiers, single point view of portfolio across industry segments, and their relative market position.
Chapter 22 – Competition Analysis
In this chapter, readers can find a comprehensive list of all the leading stakeholders in the PD-1/PD-L1 inhibitors market, along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments. Players featured in the PD-1/PD-L1 inhibitors market report include Bristol-Myers Squibb, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca, Merck KGaA and Pfizer Inc.
Chapter 23 – Assumptions and Acronyms Used
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.
Chapter 24 – Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the PD-1/PD-L1 inhibitors market.
Sources and Primary Research Splits (%)
Industry Interactions
Key Designations
C - Level Executives
Marketing Directors
Product Managers
Business Development Officers
Production Managers
Procurement Heads
Sales Executives
Stakeholder Category
Distributors
Traders
Raw Material Suppliers
Industry Experts
Consumptions
key Questions
Current Market Dynamics and Challenges
Yesteryear Trends
Market Characteristics
Market Performance and Growth Quadrants
Competition Structure and Market Structure
Strategic Growth Initiatives
Near-term and Long-term Market Growth Prospects
Market Segment Splits and Authenticity
Opinions on Market Projections and Validity of Assumptions
References Catalogue
Industry Publications
World Health Organizations (WHO)
National Institute of Health (NIH)
Factiva
Company Press Releases
Annual Reports and Investor Presentations
Research Papers
Government Websites and Publications
Company Websites,
Morningstar
A recent market study published by Future Market Insights (FMI) on the PD-1/PD-L1 inhibitors market offers global industry analysis for 2015-2021 & opportunity assessment for 2022-2030. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the PD-1/PD-L1 inhibitors market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may make a huge impact on the development of the PD-1/PD-L1 inhibitors market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the PD-1/PD-L1 inhibitors market in the coming years. The report provides detailed information about the current and future growth prospects of the PD-1/PD-L1 inhibitors market in the most comprehensive way for better understanding of readers.
Key Segments of PD-1/PD-L1 inhibitors Market
FMI’s study on the PD-1/PD-L1 inhibitors market offers information divided into four important segments— product, indication, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Product
Nivolumab
Pembrolizumab
Atezolizumab
Avelumab
Durvalumab
Indication
Melanoma
Non-Small Cell Lung Cancer (NSCLC)
Renal Cell Carcinoma (RCC)
Head and Neck Squamous Cell Cancer (HNSCC)
Bladder Cancer
Merkel Cell Carcinoma (MCC)
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Chapter 1 – Executive Summary
The report commences with the executive summary of the PD-1/PD-L1 inhibitors market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the PD-1/PD-L1 inhibitors market as well as the key trends impacting the market.
Chapter 2 – Market Overview
Readers can find detailed taxonomy and product definition of the PD-1/PD-L1 inhibitors market, in this chapter, which help readers understand basic information about PD-1/PD-L1 inhibitors.
Chapter 3 – Key Market Trends
This section highlights the key trends impacting the PD-1/PD-L1 inhibitors market, which will help readers understand the current trends and their impact on market growth.
Chapter 4 – Market Background
This chapter explains the key macroeconomic factors that are expected to influence the growth of the PD-1/PD-L1 inhibitors market during the forecast period. The chapter also highlights the major forecast factors that will shape market growth. Besides, it provides key dynamics of the PD-1/PD-L1 inhibitors market, which include the drivers, restraints, and opportunity analysis. This chapter is expected to enable readers to understand the factors that are propelling the growth of the PD-1/PD-L1 inhibitors market, as well as those that are likely to hamper the growth of the PD-1/PD-L1 inhibitors market. The opportunity analysis for the PD-1/PD-L1 inhibitors will help readers understand the market opportunities, based on which they can plan their strategies.
Chapter 5 – Market Context
This chapter explains the pipeline assessment, key regulations for product launch in various countries along with disease epidemiology that are expected to influence the growth of the PD-1/PD-L1 inhibitors market during the forecast period.
Chapter 6 – COVID19 Crisis Analysis
In addition this section also provides the current and expected impact of COVID19 on the PD-1/PD-L1 inhibitors market.
Chapter 7 – Global PD-1/PD-L1 Inhibitors Market - Pricing Analysis
This section provides information on the pricing analysis from the regional and global prospects, also including pricing break up at distributor and manufacturer level.
Chapter 8 – Global PD-1/PD-L1 inhibitors Market Value (US$) Analysis 2015-2021 and Forecast 2022-2030
This section explains the global market value analysis and forecast for the PD-1/PD-L1 inhibitors market during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2022), and an incremental $ opportunity for the forecast period (2022-2030).
Chapter 9 – Global PD-1/PD-L1 inhibitors Market Analysis (2015-2021) and Forecast (2022-2030), By Product
Based on product, the PD-1/PD-L1 inhibitors market is segmented into nivolumab, pembrolizumab, atezolizumab, avelumab and durvalumab. In this chapter, readers can find information about a detailed analysis of the market by different product of PD-1/PD-L1 inhibitors and their growth over the forecast period.
Chapter 10 – Global PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast, 2022-2030, By Indication
Based on indication, the PD-1/PD-L1 inhibitors market is segmented into Melanoma, Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Head and Neck Squamous Cell Cancer (HNSCC), Bladder Cancer, Merkel Cell Carcinoma (MCC) and others. In this chapter, readers can find information on market attractive analysis based on indication.
Chapter 11 – Global PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast, 2022-2030, By Distribution Channel
Based on distribution channel, the PD-1/PD-L1 inhibitors market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. In this chapter, readers can find information on market attractive analysis based on distribution channel.
Chapter 12 – Global PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, By Region
This chapter explains how the PD-1/PD-L1 inhibitors market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).
Chapter 13 – North America PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
This chapter includes a detailed analysis of the growth of the North America PD-1/PD-L1 inhibitors market along with the country-wise assessment including the U.S. and Canada. Readers can also find key takeaways of this region, and market growth based on product, indication, distribution channel and country of PD-1/PD-L1 inhibitors in the North American region.
Chapter 14 – Latin America PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
This chapter includes the growth prospects of the PD-1/PD-L1 inhibitors market in leading countries such as Brazil, Mexico, and the rest of Latin America. Readers can find thorough information about the growth parameters of the Latin America PD-1/PD-L1 inhibitors market during 2022-2030.
Chapter 15 –Europe PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
Important growth prospects of the PD-1/PD-L1 inhibitors market based on product, indication, distribution channel, and country in several European countries such as the U.K., Germany, France, Italy, Spain, Russia, BENELUX, and Rest of Europe are included in this chapter.
Chapter 16 – South Asia PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
India, Indonesia, Malaysia, Thailand, and the rest of South Asia are the leading countries/regions in South Asia that are the prime subjects of assessment to obtain the growth prospects of the South Asia PD-1/PD-L1 inhibitors market, in this chapter, readers can find thorough information about the growth parameters of the South Asia PD-1/PD-L1 inhibitors market during 2030.
Chapter 17 – East Asia PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
Detailed information about factors such as incremental opportunity, Y-O-Y growth, and regional trends that are impacting the growth of the East Asia PD-1/PD-L1 inhibitors market are included in this chapter. It also includes the growth prospects of the PD-1/PD-L1 inhibitors market in leading East Asian countries such as China, Japan, and South Korea.
Chapter 18 – Oceania PD-1/PD-L1 inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
This chapter consists of important parameters that have a huge impact on the growth of the PD-1/PD-L1 inhibitors market in Oceania, based on market segmentation, during the forecast period. The chapter also provides an overview of the drivers, restraints, and trends in the Oceania PD-1/PD-L1 inhibitors market.
Chapter 19 – Middle East & Africa PD-1/PD-L1 inhibitors Market Analysis 2015-2021 & Opportunity Assessment 2022-2030
This chapter provides information on how the PD-1/PD-L1 inhibitors market will grow in the major countries in MEA region, such as GCC Countries, South Africa, Northern Africa, Turkey and Rest of MEA during 2022-2030.
Chapter 20 – Key and Emerging Countries PD-1/PD-L1 inhibitors Market Analysis 2022 & 2030
This chapter provides information on how the PD-1/PD-L1 inhibitors market will grow in the major countries across the world during 2022 & 2030.
Chapter 21 – Market Structure Analysis
This chapter covers the market analysis of competitors based on revenue tiers, single point view of portfolio across industry segments, and their relative market position.
Chapter 22 – Competition Analysis
In this chapter, readers can find a comprehensive list of all the leading stakeholders in the PD-1/PD-L1 inhibitors market, along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments. Players featured in the PD-1/PD-L1 inhibitors market report include Bristol-Myers Squibb, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca, Merck KGaA and Pfizer Inc.
Chapter 23 – Assumptions and Acronyms Used
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.
Chapter 24 – Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the PD-1/PD-L1 inhibitors market.
Sources and Primary Research Splits (%)
Industry Interactions
Key Designations
C - Level Executives
Marketing Directors
Product Managers
Business Development Officers
Production Managers
Procurement Heads
Sales Executives
Stakeholder Category
Distributors
Traders
Raw Material Suppliers
Industry Experts
Consumptions
key Questions
Current Market Dynamics and Challenges
Yesteryear Trends
Market Characteristics
Market Performance and Growth Quadrants
Competition Structure and Market Structure
Strategic Growth Initiatives
Near-term and Long-term Market Growth Prospects
Market Segment Splits and Authenticity
Opinions on Market Projections and Validity of Assumptions
References Catalogue
Industry Publications
World Health Organizations (WHO)
National Institute of Health (NIH)
Factiva
Company Press Releases
Annual Reports and Investor Presentations
Research Papers
Government Websites and Publications
Company Websites,
Morningstar
Table of Contents
209 Pages
- 1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Technology Roadmap
- 1.5. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusions and Exclusions
- 3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Product Innovation / Development Trends
- 4. Market Background
- 4.1. Macro-Economic Factors
- 4.1.1. Global GDP Growth Outlook
- 4.1.2. Global Healthcare Expenditure Outlook
- 4.1.3. Global Pharmaceutical Market
- 4.1.4. Global Parent Market Outlook
- 4.2. Forecast Factors - Relevance & Impact
- 4.2.1. Key Players Historical Growth
- 4.2.2. Product Adoption Across Regions
- 4.2.3. Product cost
- 4.2.4. Growth in drug development
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 5. Market Context
- 5.1. Product USPs/ Features
- 5.2. ProductAdoption / Usage Analysis
- 5.3. Regulatory Scenario
- 5.4. Disease Epidemiology, By Key Indication
- 5.5. Pipeline Assessment
- 6. COVID19 Crisis Analysis
- 6.1. Current COVID19 Statistics and Probable Future Impact
- 6.2. Current GDP Projection and Probable Impact
- 6.3. Current Economic Projection as compared to 2008 financial analysis
- 6.4. COVID19 and Impact Analysis
- 6.4.1. Revenue By Product
- 6.4.2. Revenue By Country
- 6.5. 2022 Market Scenario
- 6.6. Quarter by Quarter Forecast
- 6.7. Projected recovery Quarter
- 7. Global PD-1/PD-L1 Inhibitors Market - Pricing Analysis
- 7.1. Regional Pricing Analysis By Product
- 7.2. Pricing Break-up
- 7.2.1. Manufacturer Level Pricing
- 7.2.2. Distributor Level Pricing
- 7.3. Global Average Pricing Analysis Benchmark
- 8. Global PD-1/PD-L1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast, 2022-2030
- 8.1. Historical Market Value (US$ Mn) Analysis, 2015-2021
- 8.2. Current and Future Market Value (US$ Mn) Projections, 2022-2030
- 8.2.1. Y-o-Y Growth Trend Analysis
- 8.2.2. Opportunity Analysis, 2022-2030
- 9. Global PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, By Product
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) Analysis By Product, 2015–2021
- 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2030
- 9.3.1. Nivolumab
- 9.3.2. Pembrolizumab
- 9.3.3. Atezolizumab
- 9.3.4. Avelumab
- 9.3.5. Durvalumab
- 9.4. Market Attractiveness Analysis By Product
- 10. Global PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, By Indication
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015–2021
- 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2030
- 10.3.1. Non-Small Cell Lung Cancer (NSCLC)
- 10.3.2. Head and Neck Squamous Cell Cancer (HNSCC)
- 10.3.3. Bladder Cancer
- 10.3.4. Renal Cell Carcinoma (RCC)
- 10.3.5. Melanoma
- 10.3.6. Merkel Cell Carcinoma (MCC)
- 10.3.7. Others
- 10.4. Market Attractiveness Analysis By Indication
- 11. Global PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, by Distribution Channel
- 11.1. Introduction / Key Findings
- 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015–2021
- 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2030
- 11.3.1. Hospital Pharmacies
- 11.3.2. Retail Pharmacies
- 11.3.3. Online Pharmacies
- 11.4. Market Attractiveness Analysis By Distribution Channel
- 12. Global PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, by Region
- 12.1. Introduction / Key Findings
- 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2015–2021
- 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2030
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. East Asia
- 12.3.5. South Asia
- 12.3.6. Oceania
- 12.3.7. Middle East and Africa
- 12.4. Market Attractiveness Analysis By Region
- 13. North America PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
- 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
- 13.3.1. By Country
- 13.3.1.1. U.S.
- 13.3.1.2. Canada
- 13.3.2. By Product
- 13.3.3. By Indication
- 13.3.4. By Distribution Channel
- 13.4. Market Attractiveness Analysis
- 13.5. Key Market Participants - Intensity Mapping
- 13.6. Drivers and Restraints - Impact Analysis
- 14. Latin America PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
- 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
- 14.3.1. By Country
- 14.3.1.1. Brazil
- 14.3.1.2. Mexico
- 14.3.1.3. Argentina
- 14.3.1.4. Rest of Latin America
- 14.3.2. By Product
- 14.3.3. By Indication
- 14.3.4. By Distribution Channel
- 14.4. Market Attractiveness Analysis
- 14.5. Key Market Participants - Intensity Mapping
- 14.6. Drivers and Restraints - Impact Analysis
- 15. Europe PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
- 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
- 15.3.1. By Country
- 15.3.1.1. Germany
- 15.3.1.2. Italy
- 15.3.1.3. France
- 15.3.1.4. U.K.
- 15.3.1.5. Spain
- 15.3.1.6. BENELUX
- 15.3.1.7. Russia
- 15.3.1.8. Rest of Europe
- 15.3.2. By Product
- 15.3.3. By Indication
- 15.3.4. By Distribution Channel
- 15.4. Market Attractiveness Analysis
- 15.5. Key Market Participants - Intensity Mapping
- 15.6. Drivers and Restraints - Impact Analysis
- 16. South Asia PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
- 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
- 16.3.1. By Country
- 16.3.1.1. India
- 16.3.1.2. Thailand
- 16.3.1.3. Indonesia
- 16.3.1.4. Malaysia
- 16.3.1.5. Rest of South Asia
- 16.3.2. By Product
- 16.3.3. By Indication
- 16.3.4. By Distribution Channel
- 16.4. Market Attractiveness Analysis
- 16.5. Key Market Participants - Intensity Mapping
- 16.6. Drivers and Restraints - Impact Analysis
- 17. East Asia PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
- 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
- 17.3.1. By Country
- 17.3.1.1. China
- 17.3.1.2. Japan
- 17.3.1.3. South Korea
- 17.3.2. By Product
- 17.3.3. By Indication
- 17.3.4. By Distribution Channel
- 17.4. Market Attractiveness Analysis
- 17.5. Key Market Participants - Intensity Mapping
- 17.6. Drivers and Restraints - Impact Analysis
- 18. Oceania PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
- 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
- 18.3.1. By Country
- 18.3.1.1. Australia
- 18.3.1.2. New Zealand
- 18.3.2. By Product
- 18.3.3. By Indication
- 18.3.4. By Distribution Channel
- 18.4. Market Attractiveness Analysis
- 18.5. Key Market Participants - Intensity Mapping
- 18.6. Drivers and Restraints - Impact Analysis
- 19. Middle East and Africa PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030
- 19.1. Introduction
- 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
- 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
- 19.3.1. By Country
- 19.3.1.1. GCC Countries
- 19.3.1.2. Turkey
- 19.3.1.3. South Africa
- 19.3.1.4. Rest of Middle East and Africa
- 19.3.2. By Product
- 19.3.3. By Indication
- 19.3.4. By Distribution Channel
- 19.4. Market Attractiveness Analysis
- 19.5. Key Market Participants - Intensity Mapping
- 19.6. Drivers and Restraints - Impact Analysis
- 20. Key and Emerging Countries PD-1/PD-L1 Inhibitors Market Analysis 2022 & 2030
- 20.1. Introduction
- 20.1.1. Market Value Proportion Analysis, By Key Countries
- 20.1.2. Global Vs. Country Growth Comparison
- 20.2. U.S. PD-1/PD-L1 Inhibitors Market Analysis
- 20.2.1. By Product
- 20.2.2. By Indication
- 20.2.3. By Distribution Channel
- 20.3. Canada PD-1/PD-L1 Inhibitors Market Analysis
- 20.3.1. By Product
- 20.3.2. By Indication
- 20.3.3. By Distribution Channel
- 20.4. Mexico PD-1/PD-L1 Inhibitors Market Analysis
- 20.4.1. By Product
- 20.4.2. By Indication
- 20.4.3. By Distribution Channel
- 20.5. Brazil PD-1/PD-L1 Inhibitors Market Analysis
- 20.5.1. By Product
- 20.5.2. By Indication
- 20.5.3. By Distribution Channel
- 20.6. U.K. PD-1/PD-L1 Inhibitors Market Analysis
- 20.6.1. By Product
- 20.6.2. By Indication
- 20.6.3. By Distribution Channel
- 20.7. Germany PD-1/PD-L1 Inhibitors Market Analysis
- 20.7.1. By Product
- 20.7.2. By Indication
- 20.7.3. By Distribution Channel
- 20.8. France PD-1/PD-L1 Inhibitors Market Analysis
- 20.8.1. By Product
- 20.8.2. By Indication
- 20.8.3. By Distribution Channel
- 20.9. Italy PD-1/PD-L1 Inhibitors Market Analysis
- 20.9.1. By Product
- 20.9.2. By Indication
- 20.9.3. By Distribution Channel
- 20.10. Spain PD-1/PD-L1 Inhibitors Market Analysis
- 20.10.1. By Product
- 20.10.2. By Indication
- 20.10.3. By Distribution Channel
- 20.11. BENELUX PD-1/PD-L1 Inhibitors Market Analysis
- 20.11.1. By Product
- 20.11.2. By Indication
- 20.11.3. By Distribution Channel
- 20.12. Russia PD-1/PD-L1 Inhibitors Market Analysis
- 20.12.1. By Product
- 20.12.2. By Indication
- 20.12.3. By Distribution Channel
- 20.13. China PD-1/PD-L1 Inhibitors Market Analysis
- 20.13.1. By Product
- 20.13.2. By Indication
- 20.13.3. By Distribution Channel
- 20.14. Japan PD-1/PD-L1 Inhibitors Market Analysis
- 20.14.1. By Product
- 20.14.2. By Indication
- 20.14.3. By Distribution Channel
- 20.15. South Korea PD-1/PD-L1 Inhibitors Market Analysis
- 20.15.1. By Product
- 20.15.2. By Indication
- 20.15.3. By Distribution Channel
- 20.16. India PD-1/PD-L1 Inhibitors Market Analysis
- 20.16.1. By Product
- 20.16.2. By Indication
- 20.16.3. By Distribution Channel
- 20.17. ASEAN PD-1/PD-L1 Inhibitors Market Analysis
- 20.17.1. By Product
- 20.17.2. By Indication
- 20.17.3. By Distribution Channel
- 20.18. Australia PD-1/PD-L1 Inhibitors Market Analysis
- 20.18.1. By Product
- 20.18.2. By Indication
- 20.18.3. By Distribution Channel
- 20.19. New Zealand PD-1/PD-L1 Inhibitors Market Analysis
- 20.19.1. By Product
- 20.19.2. By Indication
- 20.19.3. By Distribution Channel
- 20.20. GCC Countries PD-1/PD-L1 Inhibitors Market Analysis
- 20.20.1. By Product
- 20.20.2. By Indication
- 20.20.3. By Distribution Channel
- 20.21. Turkey PD-1/PD-L1 Inhibitors Market Analysis
- 20.21.1. By Product
- 20.21.2. By Indication
- 20.21.3. By Distribution Channel
- 20.22. South Africa PD-1/PD-L1 Inhibitors Market Analysis
- 20.22.1. By Product
- 20.22.2. By Indication
- 20.22.3. By Distribution Channel
- 21. Market Structure Analysis
- 21.1. Market Analysis by Tier of Companies
- 21.2. Market Share Analysis of Top Players (2021)
- 21.3. Market Presence Analysis
- 21.3.1. Regional Footprint by Players
- 21.3.2. Product Foot print by Players
- 22. Competition Analysis
- 22.1. Competition Dashboard
- 22.2. Competition Benchmarking
- 22.3. Competition Deep Dive (Tentative List)
- 22.3.1. Bristol-Myers Squibb Company
- 22.3.1.1. Overview
- 22.3.1.2. Product Portfolio
- 22.3.1.3. Profitability by Market Segments (Product/Channel/Region)
- 22.3.1.4. Sales Footprint
- 22.3.1.5. SWOT Analysis
- 22.3.1.6. Strategy Overview
- 22.3.1.6.1. Marketing Strategy
- 22.3.1.6.2. Product Strategy
- 22.3.1.6.3. Channel Strategy
- 22.3.2. Eli Lilly and Company
- 22.3.2.1. Overview
- 22.3.2.2. Product Portfolio
- 22.3.2.3. Profitability by Market Segments (Product/Channel/Region)
- 22.3.2.4. Sales Footprint
- 22.3.2.5. SWOT Analysis
- 22.3.2.6. Strategy Overview
- 22.3.2.6.1. Marketing Strategy
- 22.3.2.6.2. Product Strategy
- 22.3.2.6.3. Channel Strategy
- 22.3.3. F.Hoffman-La Roche AG
- 22.3.3.1. Overview
- 22.3.3.2. Product Portfolio
- 22.3.3.3. Profitability by Market Segments (Product/Channel/Region)
- 22.3.3.4. Sales Footprint
- 22.3.3.5. SWOT Analysis
- 22.3.3.6. Strategy Overview
- 22.3.3.6.1. Marketing Strategy
- 22.3.3.6.2. Product Strategy
- 22.3.3.6.3. Channel Strategy
- 22.3.4. AstraZeneca Plc
- 22.3.4.1. Overview
- 22.3.4.2. Product Portfolio
- 22.3.4.3. Profitability by Market Segments (Product/Channel/Region)
- 22.3.4.4. Sales Footprint
- 22.3.4.5. SWOT Analysis
- 22.3.4.6. Strategy Overview
- 22.3.4.6.1. Marketing Strategy
- 22.3.4.6.2. Product Strategy
- 22.3.4.6.3. Channel Strategy
- 22.3.5. Pfizer Inc
- 22.3.5.1. Overview
- 22.3.5.2. Product Portfolio
- 22.3.5.3. Profitability by Market Segments (Product/Channel/Region)
- 22.3.5.4. Sales Footprint
- 22.3.5.5. SWOT Analysis
- 22.3.5.6. Strategy Overview
- 22.3.5.6.1. Marketing Strategy
- 22.3.5.6.2. Product Strategy
- 22.3.5.6.3. Channel Strategy
- 22.3.6. Merck KGaA.
- 22.3.6.1. Overview
- 22.3.6.2. Product Portfolio
- 22.3.6.3. Profitability by Market Segments (Product/Channel/Region)
- 22.3.6.4. Sales Footprint
- 22.3.6.5. SWOT Analysis
- 22.3.6.6. Strategy Overview
- 22.3.6.6.1. Marketing Strategy
- 22.3.6.6.2. Product Strategy
- 22.3.6.6.3. Channel Strategy
- 23. Assumptions and Acronyms Used
- 24. Research Methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
